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Abstract
Topical application of vitamin K is beneficial in the treatment of various skin 
pathologies. However, its delivery to the skin is hampered by the photo-instability 
and phototoxicity of vitamin K (quinone form). Indeed, topical use of vitamin K is 
regulated in Europe owing to the photosensitive properties of this molecule. Here, 
we discuss the suitability of ester derivatives of vitamin K hydroquinone (VKH), 
the active form of vitamin K, for topical applications. Notably, VKH derivatives 
have the potential to overcome the photo-instability and phototoxicity problem of 
vitamin K and act as VKH prodrugs, as demonstrated in HaCaT human keratino-
cytes. Thus, VKH prodrug is a promising strategy for topical application of vitamin 
K without the need for special protection from light.
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1. Introduction
Skin application of vitamin K shows several beneficial effects, such as suppres-
sion of pigmentation and alleviation of bruising [1–3], prophylactically limiting the 
occurrence of acneiform side effects in patients receiving the monoclonal antibody 
cetuximab [4–6] and promoting wound healing [7].
Despite these potentially beneficial effects, vitamin K is unstable in the presence 
of light [8, 9]. Indeed, application of vitamin K on the skin can result in photodeg-
radation without appropriate shielding of the application site, e.g., the face and 
hands, from light. Furthermore, in Europe, warnings have been issued regarding 
the use of vitamin K in cosmetics. The Scientific Committee on Consumer Safety 
has also reported phototoxicity of vitamin K in skin cells [10, 11]. As a result, the 
use of vitamin K as an external preparation for the skin is limited.
The molecules in the vitamin K family contain 2-methyl-1,4-naphthoquinone 
as the basic skeleton. Vitamin K molecules can be classified as phylloquinone (PK, 
vitamin K1) with a phytyl side chain at the 3-position, menaquinone (MK-n, vita-
min K2) with an isoprenyl side chain consisting of n isoprenyl groups, and menadi-
one (MD, vitamin K3) with no side chain at the 3-position. PK and MK-4 are widely 
used as pharmaceutical treatments for vitamin K deficiency and osteoporosis.
Vitamin K (quinone form) delivered intracellularly is converted into vitamin K 
hydroquinone (VKH) by two-electron reduction. VKH functions as a cofactor for 
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γ-glutamyl carboxylase (GGCX), which converts the glutamic acid (Glu) residue 
of vitamin K-dependent protein into the γ-carboxyglutamic acid (Gla) residue as 
a post-translational modification. Subsequently, VKH is oxidized to vitamin K 
epoxide (VKO). In addition, VKO is reduced to vitamin K (quinone form) to form 
the vitamin K cycle. Therefore, it is necessary to deliver sufficient VKH to the target 
site to achieve efficacy.
The active forms of PK and MK-4 are phyllohydroquinone (PKH) and mena-
hydroquinone-4 (MKH), respectively. However, these compounds cannot be used 
as preparations because they show extreme instability via oxidation. Therefore, PK 
and MK-4 that are stable against oxidation are used clinically. However, as described 
above, vitamin K (quinone form) is extremely unstable upon exposure to light. 
Thus, strict control of lighting is required during formulation, distribution, storage 
at medical institutions, and administration to patients. To achieve full efficacy of 
vitamin K, formulations with low photodegradation and phototoxicity are needed 
for effective topical delivery of VKH. The concepts underlying the delivery system 
of VKH using Vitamin K are shown in Figure 1.
2. Mechanisms of photodegradation and phototoxicity of vitamin K
Analysis of the PK photolysis reaction by Hangarter et al. showed that charge 
transfer from the β,γ-double bond of the isoprenyl side chain to the quinone moiety 
Figure 1. 
Schematic illustration of the vitamin K cycle.
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initiates intramolecular proton transfer from the side chain and yields a 1,3-quinone 
methide (meta-quinone methide) as a mixture of singlet and triplet species diradi-
cal in polar solvents, subsequently forming 1,2-quinone methide (ortho-quinone 
methide), which can be used to generate PK chromenol [9]. Chromenol levels tend 
to increase with irradiation time, and this compound is expected to be the final 
product of photodegradation of vitamin K [9, 12, 13].
Vitamin K is also expected to cause two types of phototoxicity during the 
abovementioned series of photodegradation processes. After acquiring the excited 
state via light absorption, some chemicals cause oxidative damage to biological 
components, such DNA and proteins, through the generation of free radicals (type 
I reaction) by the electron rearrangement reaction and the generation of singlet 
oxygen from triplet oxygen (ground state) by the energy rearrangement reaction 
(type II reaction) [14, 15].
We have previously confirmed that irradiation of PK and MK-4 with UVA 
increases singlet oxygen generation, intracellular reactive oxygen species (ROS) 
generation, and cytotoxicity in HaCaT human keratinocytes. Thus, vitamin K has 
phototoxic properties [12, 13]. Moreover, 1,3-quinone methide diradical and 1,2-qui-
none methide, which are produced during the photodegradation of vitamin K, are 
highly reactive and show phototoxicity via type I reactions. Additionally, singlet 
oxygen generation through a type II reaction is an early-stage phototoxic reaction that 
generates additional secondary ROS [16]. Singlet oxygen is also known to promote the 
peroxidation of skin surface lipids, resulting in the induction of skin inflammation 
[17]. Because no enzymes are known to scavenge singlet oxygen in the body, singlet 
oxygen is thought to exhibit extremely strong cytotoxicity. Figure 2 shows a sche-
matic diagram of the processes of vitamin K photodegradation and phototoxicity.
Figure 2. 
Schematic diagram of vitamin K photodegradation and phototoxicity.
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3.  Application of VKH derivatives to overcome vitamin K 
photodegradation and phototoxicity
3.1 VKH derivatives strategy for applying vitamin K to the skin
Vitamin K photodegradation and phototoxicity are derived from its quinone 
structure [9]. Therefore, as far as it has a quinone structure, the photoreaction is 
unavoidable. We have previously synthesized VKH derivatives without a quinone 
structure in which the two hydroxyl groups of the VKH are protected by ester 
bonds. In addition, we have previously reported cationic VKH derivatives which 
have N,N-dimethylglycine (DMG) and anionic VKH derivatives which have 
succinic acid (SUC) as promoieties (Figure 3) can deliver VKH to the liver and to 
hepatocellular carcinoma cells by being hydrolyzed without a reductive activation 
process and exhibit strong antitumor effects compared with Vitamin K [18–20]. 
Accordingly, these VKH derivatives may act as delivery systems for VKH to avoid 
photodegradation and phototoxicity. Also, Vitamin K (quinone-type) is the diffi-
culty in dose adjustment owing to its high lipid solubility and insolubility in aque-
ous media. Since VKH derivatives are designed in the form of powders, they are 
comparatively easy to prepare. Moreover, VKH derivatives are hydrophilic and can 
be dispersed in aqueous media. These aqueous formulations can be used in in vitro 
experiments without using solubilizing agents such as surfactants.
Here, we assessed their photostability and phototoxicity in order to further 
development of a vitamin K skin application.
3.2 Evaluation of the photostability of VKH derivatives
The ethanol solutions of PK, MK-4, phyllohydroquinone derivatives (PKH-
DMG and PKH-SUC), and menahydroquinone-4 derivatives (MKH-DMG and 
MKH-SUC) in quartz cells were exposed to artificial sunlight (12000 lx) from the 
vertical direction at 25°C with and without shading. The residual concentrations 
were determined by liquid chromatography tandem mass spectrometry [12, 13].
All samples were photodegraded according to the apparent first-order rate equa-
tion by artificial sunlight irradiation, and their apparent first order rate constants 
(k) and half-lives (t1/2) of degradation are shown in Table 1. The concentrations of 
vitamin K (quinone form) and DMG ester derivatives were unchanged under shad-
ing, whereas the concentrations of SUC ester derivatives decreased both with and 
without shading. The decreased concentration of with shading was related to hydro-
lysis of the bis-ester to monoesters. The difference in the degree of hydrolysis for 
DMG and SUC ester derivatives are probably due to the stability of the ester bonds.
Figure 3. 
Structure of the VKH derivatives and hydrolytic of VKH derivatives to VKH.
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The half-lives of PK and MK-4 irradiated with artificial sunlight were 0.125 
and 0.08 h, respectively. Moreover, the half-lives of PKH-SUC and MKH-SUC 
were approximately 5- and 3-fold more stable than those of PK and MK-4, 
respectively, although the stability was not greatly improved. In contrast, the 
half-life of PKH-DMG was approximately 40-fold greater than that of PK, and 
the half-life of MKH-DMG was approximately 50-fold greater than that of MK-4, 
supporting that high light stability could be ensured against artificial sunlight. 
Note that no formation of chromenol was observed from irradiating the VKH 
derivatives.
The wavelength distribution of sunlight is wide from ultraviolet to infrared. 
To examine the wavelength characteristics of photodegradation, the photo-
stability of quinone-type vitamin K and VKH derivatives was evaluated after 
irradiation with monochromatic light at 279, 341, 373, 404, or 435 nm. Table 2 
shows the photodegradation rate (k) and the irradiation energy of each wave-
length at which the residual concentration reaches half (E1/2). Photodegradation 
of PK and MK-4 occurred at all measured wavelengths (279–435 nm), and 
the decomposition rate accelerated with shorter wavelengths. By contrast, the 
photodegradation of PKH-DMG and MKH-DMG accelerated at a wavelength of 
279 nm. In addition, the degradation of PKH-SUC and MKH-SUC occurred at 
all wavelengths, and the photodegradation rates were almost the same at wave-
lengths above 341 nm. Therefore, these findings clarified that decomposition at 
wavelengths above 341 nm involved hydrolysis to the monoester, but not photo-
degradation, and photodegradation of PKH-SUC and MKH-SUC was accelerated 
at a wavelength of 279 nm.
The above results clearly confirmed that the VKH derivative is more stable to 
sunlight than vitamin K (quinone form) and has a narrow wavelength range for 
photodegradation.
Compounda Irradiation conditions k (h−1) t1/2 (h)
PK Sunlight 5.532 0.125
Shadingb -c -c
PKH-DMG Sunlight 0.140 4.950
Shadingb -c -c
PKH-SUC Sunlight 1.219 0.569
Shadingb 0.577 1.201
MK-4 Sunlight 8.239 0.084
Shadingb -c -c
MKH-DMG Sunlight 0.167 4.150
Shadingb -c -c
MKH-SUC Sunlight 2.796 0.248
Shadingb 0.883 0.785
aThe initial concentration was 1 μM in ethanol.
bDuring irradiation, the compound was covered with aluminum foil to provide shade.
cNo decomposition.
Table 1. 
Apparent first order rate constants (k) and half-lives (t1/2) of degradation of vitamin K and VKH derivatives 
in ethanol under irradiation using artificial sunlight (12000 lx) at 25°C.
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3.3 Evaluation of phototoxicity
To confirm whether the VKH derivatives had phototoxic properties, singlet 
oxygen generation, intracellular ROS generation, and cytotoxicity after irradiation 
with UVA were evaluated in HaCaT cells [12, 13].
Figure 4 shows the amounts of singlet oxygen produced by each compound 
(200 μM) irradiated with UVA (15 J/cm2) in phosphate-buffered saline (PBS). 
Compounda Wavelength (nm) k (J−1 × cm2) E1/2 (J × cm
−2)






























aThe initial concentration was 1 μM in ethanol.
bNo decomposition.
Table 2. 
The rate constants (k) and half-lives (E1/2) of degradation of vitamin K and VKH derivatives in ethanol under 
different irradiation intensities of monochromatic light at 25°C.
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Ketoprofen was used as a positive control, and sulisobenzone was used as a negative 
control. Vitamin K (quinone form) showed singlet oxygen generation depending on 
UVA irradiation energy, whereas VKH derivatives showed almost no singlet oxygen 
generation.
Analysis of intracellular ROS generation and cell viability following UVA irra-
diation at the time of MK-4, MKH-DMG, or MKH-SUC addition (50 μM) in HaCaT 
cells is shown in Table 3. MK-4 irradiated with UVA (5 J/cm2) increased intracel-
lular ROS generation and decreased cell viability, whereas the MKH derivative did 
not. Similar trends were observed with PK and PKH derivatives [12].
Figure 4. 
Singlet oxygen generation in aqueous solutions of various compounds (200 μM) exposed to UVA (15 J/cm2). 
Data represent means ± standard deviations (n = 3).




Cell viabilityb (%control without UVA)
Control 0 100 ± 6.19 100 ± 6.04
5 275 ± 22.0 86.6 ± 5.44
MK-4 0 99.2 ± 6.87 104 ± 2.40
5 1150 ± 131 11.3 ± 2.17
MKH-DMG 0 126 ± 6.63 104 ± 1.93
5 282 ± 4.40 101 ± 2.00
MKH-SUC 0 125 ± 4.54 93.9 ± 4.79
5 271 ± 15.5 88.8 ± 6.07
aCells were treated with PBS containing 50 μM MK-4, MKH-DMG, or MKH-SUC. Data represent means ± 
standard deviations (n = 3).
bCell viability was measured at 24 h after UVA irradiation.
Table 3. 
Percent of intracellular ROS generation and cell viability in HaCaT cells in aqueous solutions of vitamin K and 
VKH derivatives with or without UVA irradiation (5 J/cm2).
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As mentioned above, the photodegradation and phototoxicity of vitamin K (qui-
none form) is charge transfer from the β, γ-double bond of the isoprenyl side chain 
to the quinone moiety initiates intramolecular proton transfer from the side chain. 
Since VKH derivatives in which the two hydroxyl groups were protected by ester 
bond, it is considered that the charge transfer from the isoprenyl side chain that 
triggers a photochemical reaction was suppressed. These results strongly supported 
that VKH derivatives without a quinone structure did not show the same photo-
degradation and phototoxicity as vitamin K (quinone form) and may therefore be 
applied topically to the skin.
4. VKH delivery into HaCaT cells with vitamin K and VKH derivatives
To confirm whether VKH derivatives function as VKH prodrugs in skin-
derived cells, the delivery properties of VKH to HaCaT cells were evaluated  
[12, 13]. Table 4 shows the area under the curve (AUC) of intracellular VKO up to 
72 h after the administration of MK-4 and VKH derivatives to HaCaT cells. VKO 
was used as an index of VKH because it is stoichiometrically produced from VKH 
after functioning as a cofactor for GGCX.
The AUCVKO (0-72h) values of PKH-DMG and PKH-SUC were 0.741- and 22.9-fold 
higher than that of PK, respectively. Additionally, the AUCVKO (0-72h) values of MKH-
DMG and MKH-SUC were 1.02- and 1.64-fold higher than that of MK-4, respectively.
Based on these findings, vitamin K (quinone form) and VKH derivatives are 
converted to VKH in HaCaT cells and function as cofactors for GGCX. Thus, VKH 
derivatives can function as prodrugs of VKH. Furthermore, VKH derivatives could 
deliver VKH at concentrations equal to or higher than vitamin K (quinone form).
5. Conclusion
Although many studies have supported the application of vitamin K for the 
treatment of skin pathologies, this compound is difficult to use as an external 
preparation to the skin owing to its photo-instability and phototoxic properties. 
The photodegradation and phototoxicity of vitamin K are derived from its quinone 
structure. Avoiding chromenol formation may suppress photodegradation via sin-
glet oxygen and radical formation. Moreover, VKH derivatives in which the quinone 
structure is protected by ester bonds do not show chromenol formation and can be 
used to overcome the photo-instability and phototoxicity associated with vitamin 
Compounda AUCVKO(0–72h) (nmol × h/mg of protein)
PK 1.176 ± 0.056
PKH-DMG 0.872 ± 0.138
PKH-SUC 26.967 ± 2.030
MK-4 10.543 ± 0.795
MKH-DMG 10.786 ± 1.696
MKH-SUC 17.304 ± 1.068
aCells were treated with medium containing 5 μM compounds. Data represent means ± standard deviations (n = 3).
Table 4. 
Area under the curve over 72 h of VKO treated with PK, PKH derivatives, MK-4 or MKH derivatives in 
HaCaT cells.
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K while promoting VKH delivery to skin cells. Thus, VKH derivatives may be used 
for application to sites where shading may be difficult, as alternatives to vitamin K 
(quinone form).
Acknowledgements
This work was funded by JSPS KAKENHI (grant number: 20 K16066).
Conflict of interest
The authors declare no conflict of interest.
© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
10
Vitamin K - Recent Advances, New Perspectives and Applications for Human Health
[1] Lou WW, Quintana AT, 
Geronemus RG, Grossman MC. Effects 
of topical vitamin K and retinol on 
laser-induced purpura on nonlesional 
skin. Dermatologic Surgery 1999;25: 
942-944
[2] Lopes LB, Speretta FFF, Vitoria M, 
Bentley LB. Enhancement of skin 
penetration of vitamin K using 
monoolein-based liquid crystalline 
systems. European Journal of 
Pharmaceutical Sciences 2007;32:209-215
[3] Cohen JL, Bhatia AC. The role of 
topical vitamin K oxide gel in the 
resolution of postprocedural purpura. 
Journal of Drugs in Dermatology 
2009;8:1020-1024
[4] Ocvirk J. Management of cetuximab-
induced skin toxicity with the pro-
phylactic use of topical vitamin K1 
cream. Radiology and Oncology 2010; 
44:265-266
[5] Pinta F, Ponzetti A, Spadi R, 
Fanchini L, Zanini M, Mecca C, et al. 
Pilot clinical trial on the efficacy of 
prophylactic use of vitamin K1-based 
cream (Vigorskin) to prevent cetuximab-
induced skin rash in patients with 
metastatic colorectal cancer. Clinical 
Colorectal Cancer 2014;13:62-67
[6] Gaiser MR, Lorenzen S, Merx K, 
Trojan J, Ocvirk J, Ettrich TJ, et al. 
Evaluation of EGFR inhibitor-mediated 
acneiform skin toxicity within the 
double-blind randomized EVITA trial: A 
thorough gender-specific analysis using 
the WoMo score. Cancer Med 2019
[7] Hemmati AA, Houshmand G, 
Ghorbanzadeh B, Nemati M, 
Behmanesh MA. Topical vitamin K-1 
promotes repair of full thickness wound 
in rat. Indian Journal of Pharmacology 
2014;46:409-412
[8] Teraoka R, Matsuda Y. Stabilization-
oriented preformulation study of 
photolabile menatetrenone (vitamin K2). 
International Journal of Pharmaceutics 
1993;93:85-90
[9] Hangarter MA, Hormann A, 
Kamdzhilov Y, Wirz J. Primary 
photoreactions of phylloquinone 
(vitamin K-1) and plastoquinone-1 in 
solution. Photochemical and Photo-
biological Sciences 2003;2:524-535
[10] Official Journal of the European 
Union., 2009. Commission Directive 
2009/6/EC of 4 February 2009 
amending Council Directive 76/768/
EEC, concerning cosmetic products, for 
the purpose of adapting Annexes II and 
III thereto to technical progress. https://
eur-lex.europa.eu/legal-content/EN/
TXT/HTML/?uri=CELEX:32009L0006
&from=GA. (Accessed on 22 February  
2021).
[11] Scientific Committees on Consumer 
Safety of the European Comission,. 2010. 
Opinion on Vitamin K1 (Phytonadione). 
https://ec.europa.eu/health/sites/health/
files/scientific_committees/consumer_
safety/docs/sccs_o_014.pdf. (Accessed on 
22 February 2021).
[12] Goto S, Setoguchi S, Nagata-Akaho N, 
Terada K, Watase D, Yamakawa H, et al. 
Ester derivatives of phyllohydroquinone 
effectively deliver the active form of 
vitamin K-1 topically, owing to their 
non-photosensitivity. European Journal 
of Pharmaceutical Sciences 2020;155:8
[13] Goto S, Setoguchi S, Yamakawa H, 
Watase D, Terada K, Matsunaga K, et al. 
Prodrugs for skin delivery of 
menahydroquinone-4, an active form of 
vitamin K-2(20), could overcome the 
photoinstability and phototoxicity of 
vitamin K-2(20). International Journal 
of Molecular Sciences 2019;20:13
[14] Foote CS. DEFINITION OF TYPE-I 
AND TYPE-II PHOTOSENSITIZED 
References
11
Overcoming the Photochemical Problem of Vitamin K in Topical Application
DOI: http://dx.doi.org/10.5772/intechopen.99310
OXIDATION. Photochemistry and 
Photobiology 1991;54:659-
[15] Baptista MS, Cadet J, Di Mascio P, 
Ghogare AA, Greer A, Hamblin MR, et 
al. Type I and type II photosensitized 
oxidation reactions: Guidelines and 
mechanistic pathways. Photochemistry 
and Photobiology 2017;93:912-919
[16] Girotti AW, Kriska T. Role of lipid 
hydroperoxides in photo-oxidative 
stress signaling. Antioxidants and Redox 
Signaling 2004;6:301-310
[17] Ryu A, Arakane K, Koide C, Arai H, 
Nagano T. Squalene as a target molecule 
in skin hyperpigmentation caused by 
singlet oxygen. Biological and 
Pharmaceutical Bulletin 2009;32: 
1504-1509
[18] Takata J, Karube Y, Hanada M, 
Matsunaga K, Matsushima Y, Sendo T, et 
al. VITAMIN-K PRODRUGS. 1. 
Synthesis of amino acid esters of 
menahydroquinone-4 and enzymatic 
reconversion to an active form. 
Pharmaceutical Research 1995;12:18-23
[19] Takata J, Karube Y, Hanada M, 
Matsunaga K, Matsushima Y, Sendo T, et 
al. Vitamin K prodrugs. 2. Water-soluble 
prodrugs of menahydroquinone-4 for 
systemic site-specific delivery. 
Pharmaceutical Research 1995;12: 
1973-1979
[20] Takata J, Karube Y, Hanada M, 
Matsunaga K, Iwasaki H. Prodrug for 
bioreductive activation-independent 
delivery of menahydroquinone-4: 
Human liver enzymatic activation and 
its action in warfarin-poisoned human 
liver. Biological and Pharmaceutical 
Bulletin 1999;22:172-178
